other material
confidence high
sentiment positive
materiality 0.50
bioAffinity Technologies announces Australian patent acceptance for lung health platform
bioAffinity Technologies, Inc.
- IP Australia accepted patent application AU 2019253111 for a flow cytometry-based platform to detect multiple lung diseases.
- The patent covers methods using fluorescent probes to identify cellular signatures of lung disease in sputum samples.
- Patent will be automatically issued in three months unless a third party files an opposition.
- Company now holds 18 awarded and 33 pending patents globally, including in the U.S., China, Japan, and Europe.
- The technology underpins CyPath® Lung, the company's noninvasive test for early-stage lung cancer.